Dystrophic Epidermolysis Bullosa Market Expected to Experience Major Growth by 2032, According to DelveInsight | Phoenicis Therapeutics, Aegle Therapeutics, Anterogen Co., Ltd., Abeona Therapeutics, Inc, Castle Creek Bioscience, Phoenix Tissue Repair, Inc

DelveInsight's "Dystrophic Epidermolysis Bullosa Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Dystrophic Epidermolysis Bullosa, historical and forecasted epidemiology as well as the Dystrophic Epidermolysis Bullosa market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Dystrophic Epidermolysis Bullosa market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Dystrophic Epidermolysis Bullosa Market Forecast
https://www.delveinsight.com/sample-request/dystrophic-epidermolysis-bullosa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Dystrophic Epidermolysis Bullosa Market Report:
• The Dystrophic Epidermolysis Bullosa market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In December 2023, Chiesi Global Rare Diseases, a division of the Chiesi Group dedicated to providing innovative therapies for rare diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted approval for FILSUVEZ® (birch triterpenes) topical gel. This approval extends to the treatment of partial thickness wounds in patients aged 6 months and older diagnosed with Junctional Epidermolysis Bullosa (JEB) and Dystrophic Epidermolysis Bullosa (DEB). FILSUVEZ marks a significant milestone as the first FDA-approved treatment for wounds associated with JEB, a rare and often severe form of EB characterized by blistering beginning in infancy.
• In September 2023, Abeona Therapeutics has disclosed the submission of a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for EB-101. Concurrently, Abeona has petitioned for a Priority Review as part of the application process.
• In May 2023, Krystal Biotech disclosed that VYJUVEK has received approval from the US Food and Drug Administration (FDA) for the treatment of patients aged 6 months and above diagnosed with Dystrophic Epidermolysis Bullosa (DEB).
• Stanford Medicine (2023) reports that while the exact number of individuals impacted by EB remains uncertain, estimates suggest that between 25,000 to 50,000 people in the United States are affected by this condition.
• According to DelveInsight's analysis, there were approximately 14,000 prevalent cases of Dystrophic Epidermolysis Bullosa (DEB) across the 7 Major Markets (7MM) in 2022. These cases are expected to rise during the forecast period from 2023 to 2032.
• In the European Union countries (EU4) and the United Kingdom, the highest prevalence of Dystrophic Epidermolysis Bullosa (DEB) was observed in the UK, with approximately 1,700 cases, followed by Germany. Conversely, France had the lowest prevalence of DEB cases in 2022.
• Key Dystrophic Epidermolysis Bullosa Companies: Phoenicis Therapeutics, Aegle Therapeutics, Anterogen Co., Ltd., Abeona Therapeutics, Inc, Castle Creek Bioscience, Phoenix Tissue Repair, Inc., Scioderm, Inc., InMed Pharmaceuticals Inc., and others
• Key Dystrophic Epidermolysis Bullosa Therapies: PTW-002 10 mg/g gel, AGLE 102, ALLO-ASC-SHEET, EB-101, FCX-007, PTR-01, SD-101-6.0 cream, INM-755 (cannabinol) cream, and others
• The Dystrophic Epidermolysis Bullosa epidemiology based on type-specific cases analyzed that the number of cases of dominant dystrophic epidermolysis bullosa is slight higher than recessive dystrophic epidermolysis bullosa
• The Dystrophic Epidermolysis Bullosa market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Dystrophic Epidermolysis Bullosa pipeline products will significantly revolutionize the Dystrophic Epidermolysis Bullosa market dynamics.

Dystrophic Epidermolysis Bullosa Overview
Dystrophic epidermolysis bullosa (DEB) is a rare genetic disorder characterized by fragile skin that is prone to blistering and scarring. It is caused by mutations in the COL7A1 gene, which provides instructions for producing type VII collagen, a protein that helps anchor the layers of the skin together. In individuals with DEB, this collagen is either missing or defective, leading to skin fragility and blister formation, particularly in response to minor trauma or friction.

Get a Free sample for the Dystrophic Epidermolysis Bullosa Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/dystrophic-epidermolysis-bullosa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Dystrophic Epidermolysis Bullosa Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Dystrophic Epidermolysis Bullosa Epidemiology Segmentation:
The Dystrophic Epidermolysis Bullosa market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Dystrophic Epidermolysis Bullosa
• Prevalent Cases of Dystrophic Epidermolysis Bullosa by severity
• Gender-specific Prevalence of Dystrophic Epidermolysis Bullosa
• Diagnosed Cases of Episodic and Chronic Dystrophic Epidermolysis Bullosa

Download the report to understand which factors are driving Dystrophic Epidermolysis Bullosa epidemiology trends @ Dystrophic Epidermolysis Bullosa Epidemiology Forecast
https://www.delveinsight.com/sample-request/dystrophic-epidermolysis-bullosa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Dystrophic Epidermolysis Bullosa Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Dystrophic Epidermolysis Bullosa market or expected to get launched during the study period. The analysis covers Dystrophic Epidermolysis Bullosa market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Dystrophic Epidermolysis Bullosa Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Dystrophic Epidermolysis Bullosa Therapies and Key Companies
• PTW-002 10 mg/g gel: Phoenicis Therapeutics
• AGLE 102: Aegle Therapeutics
• ALLO-ASC-SHEET: Anterogen Co., Ltd.
• EB-101: Abeona Therapeutics, Inc
• FCX-007: Castle Creek Bioscience
• PTR-01: Phoenix Tissue Repair, Inc.
• SD-101-6.0 cream: Scioderm, Inc.
• INM-755 (cannabinol) cream: InMed Pharmaceuticals Inc.

Discover more about therapies set to grab major Dystrophic Epidermolysis Bullosa market share @ Dystrophic Epidermolysis Bullosa Treatment Landscape
https://www.delveinsight.com/sample-request/dystrophic-epidermolysis-bullosa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Dystrophic Epidermolysis Bullosa Market Strengths
• A rising number of clinical trials are underway to assess innovative treatment approaches that have the potential to alter the progression of dystrophic epidermolysis bullosa and relieve its symptoms.
• Gene therapies for dystrophic epidermolysis bullosa are becoming a reality with the approval of VYJUVEK, the first FDA-approved topical gene therapy

Dystrophic Epidermolysis Bullosa Market Opportunities
• Currently, the lack of a cure and approved treatment presents a significant commercial opportunity for companies active in developing regenerative medicines, that is, cell and gene therapies.
• Significant advancements have been achieved in comprehending the molecular genetics and underlying mechanisms of dystrophic epidermolysis bullosa, laying the groundwork for developing potential treatments.

Scope of the Dystrophic Epidermolysis Bullosa Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Dystrophic Epidermolysis Bullosa Companies: Phoenicis Therapeutics, Aegle Therapeutics, Anterogen Co., Ltd., Abeona Therapeutics, Inc, Castle Creek Bioscience, Phoenix Tissue Repair, Inc., Scioderm, Inc., InMed Pharmaceuticals Inc., and others
• Key Dystrophic Epidermolysis Bullosa Therapies: PTW-002 10 mg/g gel, AGLE 102, ALLO-ASC-SHEET, EB-101, FCX-007, PTR-01, SD-101-6.0 cream, INM-755 (cannabinol) cream, and others
• Dystrophic Epidermolysis Bullosa Therapeutic Assessment: Dystrophic Epidermolysis Bullosa current marketed and Dystrophic Epidermolysis Bullosa emerging therapies
• Dystrophic Epidermolysis Bullosa Market Dynamics: Dystrophic Epidermolysis Bullosa market drivers and Dystrophic Epidermolysis Bullosa market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Dystrophic Epidermolysis Bullosa Unmet Needs, KOL's views, Analyst's views, Dystrophic Epidermolysis Bullosa Market Access and Reimbursement

To know more about Dystrophic Epidermolysis Bullosa companies working in the treatment market, visit @ Dystrophic Epidermolysis Bullosa Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/dystrophic-epidermolysis-bullosa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Dystrophic Epidermolysis Bullosa Market Report Introduction
2. Executive Summary for Dystrophic Epidermolysis Bullosa
3. SWOT analysis of Dystrophic Epidermolysis Bullosa
4. Dystrophic Epidermolysis Bullosa Patient Share (%) Overview at a Glance
5. Dystrophic Epidermolysis Bullosa Market Overview at a Glance
6. Dystrophic Epidermolysis Bullosa Disease Background and Overview
7. Dystrophic Epidermolysis Bullosa Epidemiology and Patient Population
8. Country-Specific Patient Population of Dystrophic Epidermolysis Bullosa
9. Dystrophic Epidermolysis Bullosa Current Treatment and Medical Practices
10. Dystrophic Epidermolysis Bullosa Unmet Needs
11. Dystrophic Epidermolysis Bullosa Emerging Therapies
12. Dystrophic Epidermolysis Bullosa Market Outlook
13. Country-Wise Dystrophic Epidermolysis Bullosa Market Analysis (2019-2032)
14. Dystrophic Epidermolysis Bullosa Market Access and Reimbursement of Therapies
15. Dystrophic Epidermolysis Bullosa Market Drivers
16. Dystrophic Epidermolysis Bullosa Market Barriers
17. Dystrophic Epidermolysis Bullosa Appendix
18. Dystrophic Epidermolysis Bullosa Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Related Reports:

Dystrophic Epidermolysis Bullosa Epidemiology https://www.delveinsight.com/report-store/dystrophic-epidermolysis-bullosa-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Dystrophic Epidermolysis Bullosa Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Dystrophic Epidermolysis Bullosa epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports by DelveInsight

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market
https://www.delveinsight.com/report-store/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market
DelveInsight's "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), historical and forecasted epidemiology as well as the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Congestive Heart Failure Market
https://www.delveinsight.com/report-store/congestive-heart-failure-market
DelveInsight's "Congestive Heart Failure Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of CHF, historical and forecasted epidemiology as well as the CHF market trends in the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan.

CDMO Market
https://www.delveinsight.com/report-store/contract-development-manufacturing-organization-market
Global CDMO market was valued at USD 100.02 billion in 2021, growing at a CAGR of 6.25% during the forecast period from 2024 to 2030, in order to reach USD 143.87 billion by 2030. Factors such as rising prevalence of various chronic and acute diseases leading to growing requirement of drugs, rising popularity of biologics as a treatment option are further expected to drive the demand for services offered by CDMOs as biologics being more complex than small molecules require elaborate facilities for product development.

Duchenne Muscular Dystrophy Market
https://www.delveinsight.com/report-store/duchenne-muscular-dystrophy-market
DelveInsight's "Duchenne Muscular Dystrophy Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of Duchenne Muscular Dystrophy historical and forecasted epidemiology as well as the Duchenne Muscular Dystrophy market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Generalized Myasthenia Gravis Market
https://www.delveinsight.com/report-store/generalized-myasthenia-gravis-gmg-market
DelveInsight's 'Generalized Myasthenia Gravis Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the Generalized Myasthenia Gravis, historical and forecasted epidemiology as well as the market trends in the United States, EU-5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.